Recent Blog Posts

View Post: Pulmonary Disease, Chronic Obstructive Clinical Trial: A Study to ...
4 Nov 2009
Official Title: “HZC102871: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic .... History of Exacerbations: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Visit 1 that required either oral corticosteroids, antibiotics and/or hospitalization. ...
View Blog: Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r...

---

View Post: Respiratory Research
Full text
The bioavailability and airway ... ...
View Blog: Although these combinations both contain an ICS and a LABA, differences exist with regard to the pharmacokinetic and pharmacodynamic properties of both components, such as the oral bioavailability and clearance, volume of distribution ..... Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, Woodcock A: Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy

---

View Post: Flovent Diskus (Fluticasone Propionate) Drug Information: Uses ...
27 Apr 2009
In a clinical trial of 111 patients with severe asthma requiring chronic oral prednisone therapy (average baseline daily prednisone dose was 14 mg), fluticasone propionate given by inhalation powder at doses of 500 and 1000 mcg twice ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: FDA Safety Changes: Visicol and Advair Diskus
21 Jun 2006
The warning was based on 21 published reports of biopsy-proven nephrocalcinosis in patients who took oral sodium phosphate and had no history of hypercalcemia or superimposed renal pathology. Twenty of these cases occurred in ... Fluticasone/salmeterol inhalation powder is available in 100-µg/50-µg, 250-µg/50-µg, and 500-µg/50-µg strengths for long-term, twice-daily use in the maintenance treatment of asthma in patients aged 4 years and older. The 250-µg/50-µg formulation ...
View Blog: Medscape Gastroenterology Headlines - http://www.medscape.com/gastroenterology

---

View Post: Successful Treatment of Previously Uncontrolled Adult Asthma with ...
20 Sep 2007 by Gawchik, S. M  
In all 3 cases, BIS improved asthma control. BIS consistently increased PEF and reduced the number of urgent care visits and oral corticosteroid courses. All patients reported satisfaction with BIS therapy. .... Before receiving BIS, she was treated with adequate trials of the available ICS products, including triamcinolone acetonide, fluticasone propionate pMDI, and budesonide inhalation powder, as well as trials of add-on montelukast sodium, zafirlukast, ...
View Blog: Annals of Pharmacotherapy current issue - http://www.theannals.com/

---

View Post: Advances With Inhaled Corticosteroids
28 Dec 2006
The American College of Allergy, Asthma and Immunology (ACAAI) conference symposium on "Inhaled Corticosteroids," held November 10, 2006 in Philadelphia, Pennsylvania, summarized studies that related the pharmacokinetics of the drug ... For the active form of beclomethasone dipropionate, beclomethasone monopropionate, oral bioavailability is 26%. Flunisolide exhibits 7% oral bioavailability. In contrast, both fluticasone propionate and ciclesonide have a negligible oral ...
View Blog: Medscape Headlines - http://www.medscape.com/home

---

View Post: Recent Advances in the Treatment Of Asthma
Pharmainfo.net
10 Sep 2009 by santosh kumar. JH   ...
View Blog: http://www.pharmainfo.net/

---

View Post: FDA Safety Changes: Advair Diskus and Vfend
20 Aug 2008
The FDA has approved revisions to the safety labeling for fluticasone propionate plus salmeterol xinafoate inhalation powder and voriconazole tablets, injection, and oral suspension. ... Fluticasone/salmeterol inhalation powder is a combination corticosteroid/long-acting β2-adrenergic agonist product indicated for the maintenance treatment of asthma in patients aged 4 years and older and for the maintenance treatment of COPD. St. John's Wort Contraindicated With ...
View Blog: Medscape Pulmonary Medicine Headlines - http://www.medscape.com/pulmonarymedicine

---

View Post: New Guidelines for the Diagnosis and Management of Asthma 2008 ...
27 Feb 2009
The use of oral systemic beta2-agonists and regularly scheduled inhaled SABAs is not recommended due to increased adverse events and the potential for poorly controlled asthma. The use of a SABA more than two days ..... In a 2007 study comparing fluticasone/salmeterol versus budesonide/formoterol, the authors concluded that twice-daily treatment with fluticasone/salmeterol and budesonide/formoterol improved symptoms and lung function in patients with persistent asthma. ...
View Blog: 快樂小藥師:: 痞客邦PIXNET :: - http://mulicia.pixnet.net/blog

---